country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

40 Results for "

CaMKK

" in MedChemExpress (MCE) Product Catalog:

Products (40)

Sort by :

Categories

By Targets

Species:

Tags:

Sources:

Hosts:

Reactivities:

Applications:

Isotypes:

Conjugations:

Clonalities:

Modifications:

Products

STO-609

39 Publications Verification

Cat. No.: HY-19805

CAS No.: 52029-86-4

Target:

CaMK AMPK Autophagy

Research Areas:

Metabolic Disease

STO-609 is a selective and cell-permeable inhibitor of the Ca ²⁺/calmodulin-dependent protein kinase kinase (CaM-KK), with K_i values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC₅₀ ~0.02 g/ml.

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Setmelanotide

8 Cited Publications

Cat. No.: HY-19870

CAS No.: 920014-72-8

Synonyms: RM-493; BIM-22493; IRC-022493

Target:

Melanocortin Receptor Calmodulin AMPK

Setmelanotide (RM-493) is a blood-brain barrier-permeable, selective MC4R agonist with a K_i value of 2.1 nM for hMC4R. Setmelanotide activates the CaMKK2/AMPK signaling pathway. Setmelanotide mediates body weight homeostasis, feeding regulation and energy expenditure modulation; it reduces food intake, induces weight loss, decreases obesity severity, increases daytime activity and energy expenditure, lowers levels of leptin, triglycerides, fasting insulin and diastolic blood pressure, improves insulin sensitivity, glucose tolerance and fatty liver condition, and reverses respiratory depression. Setmelanotide is applicable to research related to obesity, hyperinsulinemia, fatty liver and respiratory depression .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Setmelanotide monoacetate

8 Cited Publications

Cat. No.: HY-19870C

CAS No.: 2759937-80-7

Synonyms: RM-493 monoacetate; BIM-22493 monoacetate; IRC-022493 monoacetate

Target:

Melanocortin Receptor Calmodulin AMPK

Research Areas:

Cardiovascular Disease Metabolic Disease Inflammation/Immunology

Setmelanotide monoacetate (RM-493 monoacetate) is a blood-brain barrier-permeable, selective MC4R agonist with a K_i value of 2.1 nM for hMC4R. Setmelanotide monoacetate activates the CaMKK2/AMPK signaling pathway. Setmelanotide monoacetate mediates body weight homeostasis, feeding regulation and energy expenditure modulation; it reduces food intake, induces weight loss, decreases obesity severity, increases daytime activity and energy expenditure, lowers levels of leptin, triglycerides, fasting insulin and diastolic blood pressure, improves insulin sensitivity, glucose tolerance and fatty liver condition, and reverses respiratory depression. Setmelanotide monoacetate is applicable to research related to obesity, hyperinsulinemia, fatty liver and respiratory depression .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Marein

3 Cited Publications

Cat. No.: HY-N7676

CAS No.: 535-96-6

Category:

Cardiovascular Disease Flavonoids Chalcones Neurological Disease Phenols Polyphenols Plants Other Families Extract Disease Research Fields

Target:

AMPK HDAC

Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC₅₀ of 100 μM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

HS-276

2 Cited Publications

Cat. No.: HY-147141

CAS No.: 2767422-72-8

Purity: 98.93%

Target:

IRAK TNF Receptor Casein Kinase Interleukin Related

Research Areas:

Inflammation/Immunology

HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K_i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC₅₀ values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 reduces the expression of TNF, IL-6, and IL-1β. HS-276 can be used for rheumatoid arthritis (RA) research .

Compare